Selective Nerve Root Blocks — CPB 0722 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0722 governing transforaminal epidural steroid injection (TFESI) coverage, effective October 21, 2025. If your practice bills CPT 64479, 64480, 64483, or 64484 for Aetna members, the frequency and session limits in this updated Aetna transforaminal epidural injection coverage policy are what stand between you and a claim denial.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Selective Nerve Root Blocks
Policy Code	CPB 0722
Change Type	Modified
Effective Date	October 21, 2025
Impact Level	High
Specialties Affected	Pain Management, Interventional Radiology, Neurosurgery, Orthopedic Surgery, Physical Medicine & Rehabilitation
Key Action	Audit your TFESI billing against the updated session, frequency, and response-criteria limits before submitting claims after October 21, 2025

---

Aetna Transforaminal Epidural Injection Coverage Criteria and Medical Necessity Requirements 2025

The Aetna TFESI coverage policy draws a sharp line between diagnostic and therapeutic injections — and holds each to different standards. Get these wrong and you're looking at a claim denial before the procedure is even reviewed on clinical merit.

For diagnostic TFESIs (CPT 64479 for cervical/thoracic, CPT 64483 for lumbar/sacral), Aetna requires imaging guidance — fluoroscopy or CT — and limits coverage to three specific scenarios. First, when classic mono-radiculopathy symptoms exist but imaging fails to show a structural cause. Second, when imaging shows a lesion at an adjacent nerve root — not the symptomatic one. Third, when the clinical picture fits nerve root disease but could also be distal nerve or joint disease. If your patient doesn't fit one of those three buckets, the diagnostic injection won't meet medical necessity.

For therapeutic TFESIs, Aetna requires that non-invasive treatment has already failed. Your documentation needs to show that physical therapy and non-narcotic analgesics were tried and failed, or that the member became intolerant to them. Radicular pain must also be consistent with radiologic findings — not just clinically suspected. That's the bar for the first injection. Getting reimbursement for subsequent injections requires a different set of documented outcomes.

The Response Criteria That Unlock Additional Injections

This is where most billing teams get tripped up. Aetna won't cover additional therapeutic TFESIs unless the initial injection produced at least two of the following for at least two weeks:

#	Covered Indication Copy
1	50% or greater pain relief
2	Increased function or physical activity (return to work counts)
3	Reduced use of pain medications or adjunct care like physical therapy or chiropractic

Document all three if they're present. If you only have one, additional injections won't clear medical necessity. This response documentation needs to be in the record before you bill CPT 64480 or 64484 for subsequent levels or sessions.

Frequency Limits That Will Determine Your Prior Auth Strategy

This policy sets hard numerical caps. Know them before you schedule — not after.

Per session: No more than four TFESIs in a single session. That's two bilateral TFESIs at two contiguous vertebral levels in the same spinal region. Bill beyond that and you're outside the coverage policy.

Per episode of pain (six months): No more than three sessions per spinal region, and no more than 12 total TFESIs per spinal region. Sessions must be at least two weeks apart — Aetna explicitly calls out frequency under two weeks as not medically necessary.

Per 12 months: No more than four TFESI sessions per spinal region.

These aren't soft guidelines. They're hard limits. If your practice runs high-volume pain management, build these thresholds into your scheduling workflow before October 21, 2025.

---

Aetna Transforaminal Epidural Injection Exclusions and Non-Covered Indications

Several scenarios fall explicitly outside this coverage policy. Two of them carry specific code-level consequences.

CPT 64635 (destruction by neurolytic agent, paravertebral facet joint nerve, with imaging guidance — cervical or thoracic) and CPT 64636 (lumbar or sacral, each additional facet joint) are listed as not covered for the indications addressed in CPB 0722. These are facet nerve destruction codes — not TFESI codes — but they're related procedures that sometimes appear in pain management claims. Don't bill them for the same indications covered here.

Beyond specific codes, Aetna designates TFESIs as not medically necessary in four situations:

Any of these will trigger denial. If your documentation doesn't clearly match the covered criteria above, you're building a fragile claim.

---

Coverage Indications at a Glance

---

Aetna Transforaminal Epidural Injection Billing Guidelines and Action Items 2025

The billing guidelines in CPB 0722 are specific enough that your team can act on them now. Here's what to do before and after October 21, 2025.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Selective Nerve Root Blocks Under CPB 0722

Covered CPT Codes (When Selection Criteria Are Met)

Not Covered CPT Codes

Code	Type	Description	Reason Copy
64635	CPT	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT) — cervical or thoracic	Not covered for indications listed in CPB 0722
64636	CPT	Lumbar or sacral, each additional facet joint (add-on to 64635)	Not covered for indications listed in CPB 0722

Key ICD-10-CM Diagnosis Codes

---